Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study

the MARCOPOLO investigators

doi:10.1111/jdv.14083

Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study

the MARCOPOLO investigators

Department of Dermatology

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	e298-e299
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	31
Issue number	6
DOIs	https://doi.org/10.1111/jdv.14083
Publication status	Published - 2017 Jun

Bibliographical note

Funding Information:
This study was funded by Janssen-Cilag Asia Pacific Medical Affairs, Johnson & Johnson Pty Ltd.

All Science Journal Classification (ASJC) codes

Dermatology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdv.14083

Cite this

@article{c7f66f945217497a8e40d3405b904e4f,

title = "Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study",

author = "{the MARCOPOLO investigators} and Youn, {S. W.} and Kim, {B. R.} and S. Cho and Seo, {S. J.} and Lee, {E. S.} and Roh, {J. Y.} and Choi, {G. S.} and Lee, {M. G.}",

note = "Funding Information: This study was funded by Janssen-Cilag Asia Pacific Medical Affairs, Johnson & Johnson Pty Ltd.",

year = "2017",

month = jun,

doi = "10.1111/jdv.14083",

language = "English",

volume = "31",

pages = "e298--e299",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "6",

}

Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study. / the MARCOPOLO investigators.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 31, No. 6, 06.2017, p. e298-e299.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab

T2 - the MARCOPOLO study

AU - the MARCOPOLO investigators

AU - Youn, S. W.

AU - Kim, B. R.

AU - Cho, S.

AU - Seo, S. J.

AU - Lee, E. S.

AU - Roh, J. Y.

AU - Choi, G. S.

AU - Lee, M. G.

N1 - Funding Information: This study was funded by Janssen-Cilag Asia Pacific Medical Affairs, Johnson & Johnson Pty Ltd.

PY - 2017/6

Y1 - 2017/6

UR - http://www.scopus.com/inward/record.url?scp=85007565958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007565958&partnerID=8YFLogxK

U2 - 10.1111/jdv.14083

DO - 10.1111/jdv.14083

M3 - Letter

C2 - 27976465

AN - SCOPUS:85007565958

SN - 0926-9959

VL - 31

SP - e298-e299

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 6

ER -

Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this